MarginsXMarginsX
Home › Markets › Health Care › CAMP

CAMP4 Therapeutics Corporation (CAMP)

CAMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.86
+1.58% on the day
Market cap
$242.2M
Micro cap
Revenue · 2025
$3.5M
+436.5% on 2024
Net income · 2025
-$80.4M
-2298.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/0001736730-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCAMP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001736730
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.5M
Net income-$80.4M
Operating income-$52.6M
Net margin-2298.5%
Operating margin-1502.4%
Revenue growth+436.5%
Cash$109.5M
Total assets$117.8M
P/E (computed)Net income was not positive
P/S (computed)69.2×

Warning signs

Cash runway
58.5 months
$124.5M cash at September 30, 2026
Share count, 1 year
+33.9%
2025-11-03 to 2026-11-04
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$2.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$124.5M cash; operating cash flow -$6.4M a quarter.Report 2026-09-30
Shares outstanding62,754,200 (2026-11-04); 46,881,134 a year earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $77K, sold $2.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.9M-$29.0M-$8.2M$124.5MNo debt tags$5.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$1.8M-$33.5M-$12.7M$86.4MNo debt tags$4.2M10-Q 2026-08-13
Q1 2026
2026-03-31
$1.3M-$18.3M-$11.0M$99.2MNo debt tags$3.9M10-Q 2026-05-07
Q4 2025
2025-12-31
$348K-$40.3M$6.3M$109.5MNo debt tags$3.5M10-K 2026-03-05
Q3 2025
2025-09-30
$795K-$15.1M-$11.2M$75.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
$1.5M-$12.6M-$10.3M$39.1MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
$858K-$12.4M-$14.3M$49.3MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2024
2024-12-31
Not filed-$13.3M-$11.3M$64.0MNo debt tags$652K10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-12
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 195 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.4%
1 month+10.8%
3 months-15.6%
Year to date-38.0%
1 year-11.0%
From 52-week high-46.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier